KELIX bio Malta

KELIX bio Malta is a rapidly growing startup, founded in 2015, that specializes in manufacturing pharmaceutical products. Their primary focus is on the oncology sector, specifically injectable finished dosage forms (FDF) that are both FDA and EMA approved. The company’s mission centers on providing high-quality yet affordable specialty generic drugs to emerging markets, leveraging their innovation and cost leadership strategies.

Rooted in its core values of integrity, performance, quality, and care, KELIX bio actively engages with governments and healthcare partners through tenders. This allows them to significantly expand access to oncology drugs, marking a significant contribution to global healthcare. Their business model also includes partnerships with hospitals and healthcare professionals to ensure wide-reaching distribution of their products.

KELIX bio has garnered substantial investor confidence, with its investors including Development Partners International (DPI), CDC Group, European Bank for Reconstruction and Development (EBRD), among others. The company received a substantial investment of $200.00M in a Venture Round on 09 March 2022, backed by prominent investors such as British International Investment, DEG, FMO, and Proparco.

Headquartered in Malta, KELIX bio sets itself apart through uncompromising product quality and competitive pricing, positioning itself as a significant player in the pharmaceutical industry. This strategic positioning not only enhances its market share but also delivers substantial value to its stakeholders, ensuring robust returns for venture capitalists interested in impactful investments in emerging markets.